BioCentury
ARTICLE | Preclinical News

Quentis links ER stress, mitochondrial dysfunction with antitumor T cell activity

October 10, 2018 6:33 PM UTC

Researchers at Quentis Therapeutics Inc. (New York, N.Y.), Weill Cornell Medicine and Dana-Farber Cancer Institute uncovered a new mechanism of tumor immune evasion in which endoplasmic reticulum stress limits mitochondrial respiration and antitumor activity in T cells, suggesting that inhibiting the ER stress response could boost T cell activity against ovarian cancer.

Quentis, co-founded by authors Laurie Glimcher and Juan Cubillos-Ruiz, is developing potentially first-in-class cancer therapies that inhibit the ER stress response. Glimcher is Dana-Farber’s president and CEO, and Cubillos-Ruiz is assistant professor of microbiology and immunology at Weill Cornell. ...